Bokf Na Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Bokf Na increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 29.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,766 shares of the medical research company’s stock after buying an additional 6,920 shares during the quarter. Bokf Na’s holdings in IQVIA were worth $6,254,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of IQVIA in the fourth quarter worth $336,041,000. Raymond James Financial Inc. purchased a new stake in IQVIA in the fourth quarter valued at $236,120,000. American Century Companies Inc. raised its stake in shares of IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after buying an additional 905,960 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after buying an additional 902,226 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after buying an additional 712,958 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 4.1 %

IQV opened at $146.12 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s 50 day simple moving average is $165.94 and its two-hundred day simple moving average is $189.86. The firm has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.